Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform

Project description

Innovations in uterine disorder treatments for women

Women worldwide face significant challenges with uterine disorders such as excessive bleeding and fertility issues, including fibroids and endometriosis, which are critical unmet needs in women’s health. The withdrawal of Esmya, a widely used fibroid treatment, has left a gap in effective options for patients. Moreover, women suffering from endometriosis often endure poorly managed pain, highlighting the pressing need for improved treatments. Addressing these issues, the EIC-funded WOMED project introduces Womed Leaf, a drug-free intrauterine device designed to prevent adhesions and restore fertility. Building on Leaf’s innovative design, the project aims to develop a uterine drug delivery platform featuring Fibroid, a preoperative treatment for fibroids, and ReLeaf, a non-hormonal solution for managing endometriosis-related pain.

Objective

Every woman experiences some form of uterine disorder during her lifetime, including excessive bleeding, pelvic pain, and fertility issues, posing an enormous burden for women worldwide. Current treatments have limitations & painful side effects. Fibroids and endometriosis are two of the most relevant unmet needs in women health. For fibroids, an extremely common condition affecting 51% of women between 35-49, the withdrawal of Esmya, a highly appreciated treatment, has left a gap in effective options. Meanwhile, women with endometriosis (10% women in reproductive years) suffer incapacitating pain that is poorly managed with systemic analgesics. There is an urgent need for better treatments.

Womed was founded in Montpellier by Gonzague Issenmann, a serial MedTech entrepreneur, to revolutionize the women health industry by changing the paradigm of uterine disorders treatment. Womed develops safe and effective local intrauterine therapies. Our unique and patented copolymer structure allows for easy insertion, biodegradability and sustained and controlled local drug delivery. Our first product, Womed Leaf, is a drug-free intrauterine device that prevents adhesions and restores fertility. Based on Leafs design, we are developing a uterine drug delivery platform with Fibroid, a preoperative treatment for fibroids, and ReLeaf, a nonhormonal treatment to alleviate endometriosis-related pain.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

WOMED
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 493 809,50
Address
1919 ROUTE DE MENDE BATIMENT BALARD - CIT
34090 MONTPELLIER
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Occitanie Languedoc-Roussillon Hérault
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 562 697,00
My booklet 0 0